Coya Therapeutics (COYA) Other Non Operating Income (2022 - 2026)
Coya Therapeutics (COYA) posted Other Non Operating Income of $433227.0 for Q1 2026, up 33.12% sequentially from $325435.0 in Q4 2025, and up 17.04% YoY from $370165.0 in Q1 2025.
Coya Therapeutics (COYA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Other Non Operating Income for 5 years, with the latest figure at $433227.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 17.04% year-over-year to $433227.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 12.12% YoY) and the FY2025 annual result came in at $1.3 million, down 19.19% from the prior year.
- Other Non Operating Income climbed to $433227.0 in Q1 2026 per COYA's latest filing, from $325435.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $444232.0 in Q4 2024 and troughed at -$3017.0 in Q1 2022.
- A 5-year average of $242182.9 and a median of $317066.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income jumped 5523.73% in 2023, then declined 26.74% in 2025.
- Over 5 years, Other Non Operating Income stood at $16330.0 in 2022, then jumped by 969.64% to $174672.0 in 2023, then surged by 154.32% to $444232.0 in 2024, then declined by 26.74% to $325435.0 in 2025, then soared by 33.12% to $433227.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $433227.0, $325435.0, and $317066.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 408,728.00 |
| Mar 31, 2026 | 433,227.00 |
| Dec 31, 2025 | 325,435.00 |
| Sep 30, 2025 | 317,066.00 |
| Jun 30, 2025 | 319,541.00 |
| Mar 31, 2025 | 370,165.00 |
| Dec 31, 2024 | 444,232.00 |
| Sep 30, 2024 | 428,871.00 |
| Jun 30, 2024 | 344,445.00 |
| Mar 31, 2024 | 431,089.00 |
| Dec 31, 2023 | 174,672.00 |
| Sep 30, 2023 | 142,089.00 |
| Jun 30, 2023 | 158,970.00 |
| Mar 31, 2023 | 163,634.00 |
| Dec 31, 2022 | 16,330.00 |
| Sep 30, 2022 | 39,420.00 |
| Jun 30, 2022 | 10,940.00 |
| Mar 31, 2022 | -3,017.00 |